Trusted Partner in Global Healthcare APPROVED MANUFACTURING FACILITY Manufacture S fe S ® n ® [aCompany | Profi e Market Customer Base EE zctively involved in its global operations like CIS, African, South East Asian, SAARC, Latin American and Middle East Countries. GEE) Pharma has developed its marketing setup in European Countries also. GP harma’s domestic marketing team comprises of highly qualified & trained professionals. i Pharma markets its finished branded pharmaceutical formulations in Domestic market. We are a rapidly and dynamically growing up entity in the world of Pharmaceutical formulations. Our important operational areas are to manufacture, market & export of various research based niche Products & life saving medicines in regulated and semi-regulated markets We strive fora happier, healthier tomorrow. We work on total customer satisfaction to achieve leadership in pharmaceutical marketplace, products and services across the globe, through excellence in technology, based on research and development , compliance with regulatory requirements. i) of Our human resources continue to be the most valuable asset in this pursuit of leadership and the prime driving forces for our growth. Our vision is to be a leading pharmaceutical company in India and become a significant global player. ‘We aim to be present in regulated and semi-regulated markets of the world. We strive to enrich our people — our driving force, by making them as competent professionals for consistent growth of our organizationforlnjection. OME) tic9 Plant Accreditations Se ae) @ WHO GMP SD Aer WUE} ed Lon Le @ MOH Srilanka @ NAFDAC Nigeria Re MU Tare) Manufacturing The manufacturing units situated aff) Maharashtra, India on two acres of land. The factory is having two manufacturing units. One Unit has manufacturing facility of Tablets, Capsules, Cream & Ointments, Second Unit has manufacturing facility of Cephalosporin dry powder ORAL [RENE eeer cls SOLIDS Iau HARD GELATIN CAPSULES WITH PELLETS, POWDERS CAPSULES! Product Development CW Ect) SMa oo SM TMI me Nae Ls @ Analytical method development SOM ee ACEI meme erences) ea ON) WETS © Dossier compilation / submissionRegulatory — Affairs Regulatory Affairs @ Presence of a robust research infrastructure OME eels clee ae ae Le Le Leone @ RFland query responses, communication SKeMeS40 1k] AVES. aCe Olde kT TI ES @ In-house validated eCTD software @ EU/TGA/MCC/ ANVISA Hes set up Formulation, research & development to develop safe and effective therapeutic options for undiscovered and unmet medical needs. Our R&D Center conforms to international quality standards and houses advanced and up to date equipment. It has one of the most advanced infrastructures for both basic and applied research. Design of experiments (DOE) and statistical analysis have been applied widely to formulation development, and are useful in process optimization and process validation. HB cevetopment arm has dedicated teams of highly qualified scientists working on patent navigation, specializes in creating alternate and patentable processes for generic formulations, process development, scaling-up, tech transfer and registration of generic products with eCTD dossiers. Our analytical development team is capable to develop methods of analysis lay down specifications and work out quality assurance norms in relation to all the above activities The R&D facility is geared towards development of technologically Challenging products. We strive to develop cost-effective, high-quality formulations to make the life of the patient better.“ GBBprovides "ONE STOP" solution to all its business partners since from development to commercial supply Cost effective development Execution of site transfers (one stop services) Facilitating commercial supplies (export capabilities) Supply agreement with renown CMOs (Preferred partners) Intelligent project management . . Site Evaluation Presence of a robust research infrastructure Past enrollment performance on similar studies GEE has highly experienced team for product development to design formulations as per ICH Q8, Q9, Q10, QBD and expertise in designing formulations by using reverse engineering techniques with non-intringing formulations. Pre-formulation Reverse engineering gy acai sy Analytical development and validations ei it Characterisation of API, Excipients and Reference Product i Process development (Cost effective) = ke i=" . J Prototype formula | moi Process optimization Li « 4 Development as per ICHQ8/Q9/Q10/QTP/CQA/RA/DOE =, " Process evaluation and validation Stability designingwire (Caper) ical) enrich Tirta 9 raver eas eesastis PenmeN) customer centric business model to meet customer expectations fee rate use fy air In house Reevecr: Efficient and cost saving for product licenses —o_ aa’ ; DD More efficient Ensures higher regulatory level of assurance services of product qualityGlobal CIS Countri Turkmenistan Kazakhstan Uzbekistan Armenia Azerbaijan Tajikistan Ukraine Malta UK Ireland Germany ies mon Presence African Countries Philippines Ethiopia FEE wory coast I Myanmar Ea Kenya jm Senegal if Cambodia ge Uganda Gm Benin E Hong kong Ghana [EEE Cameroon a Vietnam Nigeria J [I Guineaconakry Srilanka Botswana —— BurkinaFaso [Ey Thailand — Mali BO Congo Brazzaville WR Latin American & Middle East Countriés Jamaica Yemen = Guatemala Fi Jordan Costarica = Kurdistan ES Trinidad & Tobago INQ Iraq = Chile a) [EEE Pharma believes to produce products of niche therapeutic segments and working for development of following therapeutic categories with the help of ourR & D and F &D. 1) — Immunosuppressant 2) Antiretroviral 3) _ Latest Antihypertensive =y 4) _ Latest Antidiabetic a 5) LatestAntibacterial >: 6) Lifestyle productsAPPROVED COMPANY Accreditations Available Ministry of Health PPB-Kenya WHO-GMP MoH-Stri Lanka FMHACA Ethiopia nme, =a DPML NDA Uganda FDA Ghana DPML NAFDAC Ivory Coast Nigeria